|
1
|
Pettit GR, Singh SB, Hamel E, Lin CM,
Alberts DS and Garcia-Kendall D: Isolation and structure of the
strong cell growth and tubulin inhibitor combretastatin A-4.
Experientia. 45:209–211. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marrelli M, Conforti F, Statti GA, Cachet
X, Michel S, Tillequin F and Menichini F: Biologicalpotential and
structure-activity relationships of most recently developed
vascular disrupting agents: an overview of new derivatives of
natural combretastatin a-4. Curr Med Chem. 18:3035–3081. 2011.
View Article : Google Scholar
|
|
3
|
Dowlati A, Robertson K, Cooney M, Petros
WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V,
Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR and Remick SC: A
phase I pharmacokinetic and translational study of the novel
vascular targeting agent combretastatin a-4 phosphate on a
single-dose intravenous schedule in patients with advanced cancer.
Cancer Res. 62:3408–3416. 2002.
|
|
4
|
Delmonte A and Sessa C: AVE8062: a new
combretastatin derivative vascular disrupting agent. Expert Opin
Investig Drugs. 18:1541–1548. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Beale TM, Myers RM, Shearman JW,
Charnock-Jones SD, Brenton JD, Gergely FV and Ley SV: Antivascular
and anticancer activity of dihalogenated A-ring analogues of
combretastatin A-4. Med Chem Commun. 1:202–208. 2010. View Article : Google Scholar
|
|
6
|
Shan Y, Zhang J, Liu Z, Wang M and Dong Y:
Developments of combretastatin A-4 derivatives as anticancer
agents. Curr Med Chem. 18:523–538. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
O’Boyle NM, Greene LM, Bergin O, Fichet
JB, McCabe T, Lloyd DG, Zisterer DM and Meegan MJ: Synthesis,
evaluation and structural studies of antiproliferative
tubulin-targeting azetidin-2-ones. Bioorg Med Chem. 19:2306–2325.
2011.PubMed/NCBI
|
|
8
|
Carr M, Greene LM, Knox AJ, Lloyd DG,
Zisterer DM and Meegan MJ: Lead identification of conformationally
restricted beta-lactam type combretastatin analogues: synthesis,
antiproliferative activity and tubulin targeting effects. Eur J Med
Chem. 45:5752–5766. 2010. View Article : Google Scholar
|
|
9
|
O’Boyle NM, Carr M, Greene LM, Bergin O,
Nathwani SM, McCabe T, Lloyd DG, Zisterer DM and Meegan MJ:
Synthesis and evaluation of azetidinone analogues of combretastatin
A-4 as tubulin targeting agents. J Med Chem. 53:8569–8584.
2010.PubMed/NCBI
|
|
10
|
Greene LM, O’Boyle NM, Nolan DP, Meegan MJ
and Zisterer DM: The vascular targeting agent Combretastatin-A4
directly induces autophagy in adenocarcinoma-derived colon cancer
cells. Biochem Pharmacol. 84:612–624. 2012. View Article : Google Scholar
|
|
11
|
O’Boyle NM, Carr M, Greene LM, Keely NO,
Knox AJ, McCabe T, Lloyd DG, Zisterer DM and Meegan MJ: Synthesis,
biochemical and molecular modelling studies of antiproliferative
azetidinones causing microtubule disruption and mitotic
catastrophe. Eur J Med Chem. 46:4595–4607. 2011.PubMed/NCBI
|
|
12
|
Schobert R, Effenberger-Neidnicht K and
Biersack B: Stable combretastatin A-4 analogues with sub-nanomolar
efficacy against chemoresistant HT-29 cells. Int J Clin Pharmacol
Ther. 49:71–72. 2011.PubMed/NCBI
|
|
13
|
Ohsumi K, Nakagawa R, Fukuda Y, Hatanaka
T, Morinaga Y, Nihei Y, Ohishi K, Suga Y, Akiyama Y and Tsuji T:
Novel combretastatin analogues effective against murine solid
tumors: design and structure-activity relationships. J Med Chem.
41:3022–3032. 1998. View Article : Google Scholar
|
|
14
|
Hinnen P and Eskens FA: Vascular
disrupting agents in clinical development. Br J Cancer.
96:1159–1165. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Patterson DM, Zweifel M, Middleton MR,
Price PM, Folke LK, Stratford MR, Ross P, Halford S, Peters J,
Balkissoon J, Chaplin DJ, Padhani AR and Rustin GJ: Phase I
clinical and pharmacokinetic evaluation of the vascular-disrupting
agent OXi4503 in patients with advanced solid tumors. Clin Cancer
Res. 18:1415–25. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Greene LM, Nathwani SM, Bright SA, Fayne
D, Croke A, Gagliardi M, McElligott AM, O’Connor L, Carr M, Keely
NO, O’Boyle NM, Carroll P, Sarkadi B, Conneally E, Lloyd DG, Lawler
M, Meegan MJ and Zisterer DM: The vascular targeting agent
combretastatin-A4 and a novel cis-restricted β-lactam analogue,
CA-432, induce apoptosis in human chronic myeloid leukemia cells
and ex vivo patient samples including those displaying multidrug
resistance. J Pharmacol Exp Ther. 335:302–313. 2010.
|
|
17
|
Greene LM, Carr M, Keeley NO, Lawler M,
Meegan MJ and Zisterer DM: BubR1 is required for the mitotic block
induced by combretastatin-A4 and a novel cis-restricted β-lactam
analogue in human cancer cells. Int J Mol Med. 27:715–723.
2011.PubMed/NCBI
|
|
18
|
Rubinsztein DC, Codogno P and Levine B:
Autophagy modulation as a potential therapeutic target for diverse
diseases. Nat Rev Drug Discov. 11:709–730. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Leslie EM, Deeley RG and Cole SP:
Toxicological relevance of the multidrug resistance protein 1, MRP1
(ABCC1) and related transporters. Toxicology. 167:3–23. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee HY, Chang JY, Nien CY, Kuo CC, Shih
KH, Wu CH, Chang CY, Lai WY and Liou JP: 5-Amino-2-aroylquinolines
as highly potent tubulin polymerization inhibitors. Part 2 The
impact of bridging groups at position C-2. J Med Chem.
54:8517–8525. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Romagnoli R, Baraldi PG, Salvador MK,
Preti D, Aghazadeh Tabrizi M, Brancale A, Fu XH, Li J, Zhang SZ,
Hamel E, Bortolozzi R, Basso G and Viola G: Synthesis and
evaluation of 1,5-disubstituted tetrazoles as rigid analogues of
combretastatin A-4 with potent antiproliferative and antitumor
activity. J Med Chem. 55:475–488. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rustin GJ, Galbraith SM, Anderson H,
Stratford M, Folkes LK, Sena L, Gumbrell L and Price PM: Phase I
clinical trial of weekly combretastatin A4 phosphate: clinical and
pharmacokinetic results. J Clin Oncol. 21:2815–2822. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Eikesdal HP, Schem BC, Mella O and Dahl O:
The new tubulin-inhibitor combretastatin A-4 enhances thermal
damage in the BT4An rat glioma. Int J Radiat Oncol Biol Phys.
46:645–652. 2000. View Article : Google Scholar : PubMed/NCBI
|
